Thirty-two were allocated to receive oral T 2 g, single dose, and 32 were assigned to CL 2% for 7 consecutive days.
Results: A total of 149 infants were randomized; 50 were allocated to receive racemic EPI, 51 were given ALB, and 48 received PLAC.
Also, cases that were allocated to receive I TSF were more complex cases than those receiving only conventional circular frames, which might have introduced selection bias.
On the basis of assumed unequal variance between the groups, 18 patients were allocated to receive placebo and 13 to receive ascorbic acid.
Thereafter, patients still complaining cough continued the respective ACE-inhibitor treatment, but in each arm they were allocated to receive also indomethacin 50 mg or placebo for 4 weeks according to a double-blind, cross-over design.
Animals were allocated to receive one of treatments: C0: basal diet, without CHI addition; C50, C100 and C150 received 50, 100 and 150 mg/kg BW of CHI, respectively.
After 1 week on placebo (baseline), all patients entered a double-blind protocol; 18 were allocated to receive rivastigmine and 18 placebo for the next 12 weeks (final sample with usable imaging data: 11 patients on rivastigmine, 10 on placebo).
Forty patients were allocated to receive either nebulized ceftazidime (15 mg/kg every 3 h) and amikacin (25 mg/kg once per day) or intravenous ceftazidime (90 mg/kg daily continuous infusion) and amikacin (15 mg/kg once per day).
Hajjar et al. [23] published a single center non-inferiority RCT of 502 adults undergoing cardiac surgery who were allocated to receive a transfusion if hematocrit was below 24% or 30%.
In a randomized controlled study including 297 postmenopausal women with low bone mineral density, the participants were allocated to receive capsules of 20 000 IU of vitamin D3 twice a week (high dose group) or similar looking placebo (standard dose group).
Patients were allocated to receive one of two drugs, Gatifloxacin or Cefixime.
